Treatment of newly diagnosed multiple myeloma in transplant-eligible patients

Current Hematologic Malignancy Reports

Volumn 6, Issue 2, 2011, Pages 104-112

  Kumar, Shaji ^a  

^a MAYO CLINIC   (United States)

Author keywords

IMiDs; Immunomodulatory drugs; Myeloma; Proteasome inhibitors; Risk adapted therapy; Stem cell transplantation

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; LENALIDOMIDE; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ANEMIA; ARTICLE; BONE DISEASE; CELL PROLIFERATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79957463320     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0083-0     Document Type: Article

References (51)

1. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 277 300 20610543 10.3322/caac.20073
2. SK Kumar SV Rajkumar A Dispenzieri, et al. 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 20 17975015 10.1182/blood-2007-10-116129 1:CAS:528:DC%2BD1cXivFaktrk%3D This study demonstrated improvement in survival in recent years in patients with myeloma. The improved survival is at least in part due to the introduction of new drugs
3. O Landgren RA Kyle RM Pfeiffer, et al. 2009 Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood 113 5412 7 19179464 10.1182/blood-2008-12-194241 1:CAS:528:DC%2BD1MXntVertLY%3D This study provided definitive proof that all myeloma patients have a preceding MGUS phase
4. RA Kyle SV Rajkumar 2009 Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Leukemia 23 3 9 18971951 10.1038/leu.2008.291 1:STN:280:DC%2BD1M%2FmslOgsA%3D%3D
5. SK Kumar JR Mikhael FK Buadi, et al. 2009 Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART) consensus guidelines Mayo Clin Proc 84 1095 110 19955246 10.4065/mcp.2009.0603 1:CAS:528:DC%2BC3cXhs1arsg%3D%3D
6. R Fonseca B Barlogie R Bataille, et al. 2004 Genetics and cytogenetics of multiple myeloma: a workshop report Cancer Res 64 1546 58 14989251 10.1158/0008-5472.CAN-03-2876 1:CAS:528:DC%2BD2cXhtleitb4%3D (Pubitemid 38235629)
7. H Avet-Loiseau 2007 Role of genetics in prognostication in myeloma Best Pract Res Clin Haematol 20 625 35 18070710 10.1016/j.beha.2007.08.005 1:CAS:528:DC%2BD2sXhsVSksb%2FL (Pubitemid 350225352)
8. S Wuilleme N Robillard L Lode, et al. 2005 Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma Leukemia 19 275 8 15538401 10.1038/sj.leu.2403586 1:CAS:528: DC%2BD2MXmtlOkuw%3D%3D (Pubitemid 40220593)
9. NV Smadja C Bastard C Brigaudeau D Leroux C Fruchart 2001 Groupe Francais de Cytogenetique H. Hypodiploidy is a major prognostic factor in multiple myeloma Blood 98 2229 38 11568011 10.1182/blood.V98.7.2229 1:CAS:528: DC%2BD3MXnsVCht70%3D
10. R Fonseca D Harrington MM Oken, et al. 2002 Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study Cancer Res 62 715 20 11830525 1:CAS:528:DC%2BD38Xht1Krur8%3D (Pubitemid 34126946)
11. H Avet-Loiseau JY Li C Godon, et al. 1999 P53 deletion is not a frequent event in multiple myeloma Br J Haematol 106 717 9 10468863 10.1046/j.1365-2141. 1999.01615.x 1:CAS:528:DyaK1MXmsFSjtLo%3D (Pubitemid 29434212)
12. T Facon H Avet-Loiseau G Guillerm, et al. 2001 Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy Blood 97 1566 71 11238092 10.1182/blood.V97.6.1566 1:CAS:528:DC%2BD3MXitFaltrk%3D (Pubitemid 32217218)
13. PR Greipp J San Miguel BG Durie, et al. 2005 International staging system for multiple myeloma J Clin Oncol 23 3412 20 15809451 10.1200/JCO.2005.04.242
14. S Kumar 2010 Multiple myeloma-current issues and controversies Cancer Treat Rev 36 Suppl 2 S3 11 20472186 10.1016/S0305-7372(10)70006-2
15. M Attal JL Harousseau AM Stoppa, et al. 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 91 7 8649495 10.1056/NEJM199607113350204 1:STN:280:DyaK283ms1emuw%3D%3D (Pubitemid 26240110)
16. JA Child GJ Morgan FE Davies, et al. 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875 83 12736280 10.1056/NEJMoa022340 1:CAS:528:DC%2BD3sXjsVChtLo%3D (Pubitemid 36532313)
17. J Blade L Rosinol A Sureda, et al. 2005 High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA Blood 106 3755 9 16105975 10.1182/blood-2005-03-1301 1:CAS:528:DC%2BD2MXht12ksbnO (Pubitemid 41739009)
18. A Palumbo S Bringhen B Bruno, et al. 2010 Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study Blood 115 10 1873 9 19965659 10.1182/blood-2009-09- 241737 1:CAS:528:DC%2BC3cXhtFensbnO
19. SK Kumar D Dingli MQ Lacy, et al. 2008 Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis Am J Hematol 83 614 7 18429054 10.1002/ajh.21191
20. SV Rajkumar S Hayman MA Gertz, et al. 2002 Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 4319 23 12409330 10.1200/JCO.2002.02.116 1:CAS:528:DC%2BD38Xpt1CjtLk%3D (Pubitemid 35266292)
21. SV Rajkumar E Blood D Vesole R Fonseca PR Greipp 2006 Eastern Cooperative Oncology G. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 431 6 16365178 10.1200/JCO.2005.03.0221 1:CAS:528:DC%2BD28XhsFSku7s%3D (Pubitemid 46630462)
22. SV Rajkumar L Rosinol M Hussein, et al. 2008 Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma J Clin Oncol 26 2171 7 18362366 10.1200/JCO.2007.14.1853 1:CAS:528:DC%2BD1cXms1OrtLs%3D
23. M Cavo E Zamagni P Tosi, et al. 2005 Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 106 35 9 15761019 10.1182/blood-2005-02-0522 1:CAS:528:DC%2BD2MXlvVWjs78%3D (Pubitemid 40967171)
24. HM Lokhorst I Schmidt-Wolf P Sonneveld, et al. 2008 Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma Haematologica 93 124 7 18166796 10.3324/haematol.11644 1:CAS:528:DC%2BD1cXitVOhsL4%3D (Pubitemid 351156161)
25. GJ Morgan FE Davies WM Gregory, et al. 2009 The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS [abstract] ASH Annual Meeting Abstracts 114 352
26. PG Richardson P Sonneveld M Schuster, et al. 2007 Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 3557 60 17690257 10.1182/blood-2006-08-036947 1:CAS:528:DC%2BD2sXhtlarur3K (Pubitemid 350159621)
27. S Jagannath BG Durie J Wolf, et al. 2005 Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Br J Haematol 129 776 83 15953004 10.1111/j.1365-2141.2005.05540.x 1:CAS:528:DC%2BD2MXms1ehsLw%3D (Pubitemid 40904528)
28. JL Harousseau M Attal H Avet-Loiseau, et al. 2010 Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 28 4621 29 20823406 10.1200/JCO.2009.27.9158 1:CAS:528:DC%2BC3cXhsFaitLzL This was a large phase 3 study that showed superiority of bortezomib plus dexamethasone over a VAD regimen in terms of initial treatment of myeloma prior to SCT
29. HE Oakervee R Popat N Curry, et al. 2005 PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma Br J Haematol 129 755 62 15953001 10.1111/j.1365-2141.2005.05519.x 1:CAS:528:DC%2BD2MXms1ehs7c%3D (Pubitemid 40904525)
30. CB Reeder DE Reece V Kukreti, et al. 2009 Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial Leukemia 23 1337 41 19225538 10.1038/leu.2009.26 1:CAS:528:DC%2BD1MXoslOhs7k%3D
31. S Kumar IW Flinn PG Richardson, et al. 2010 Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multi-center, randomized, phase 2 EVOLUTION study [abstract] ASH Annual Meeting Abstracts 116 621
32. P Sonneveld I Schmidt-Wolf B van der Holt, et al. 2010 HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract] ASH Annual Meeting Abstracts 116 40 This was the study to examine the role of bortezomib maintenance following autologous SCT in myeloma. The study showed improved OS in patients receiving bortezomib for induction followed by maintenance bortezomib
33. SV Rajkumar SR Hayman MQ Lacy, et al. 2005 Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 106 4050 3 16118317 10.1182/blood-2005-07-2817 1:CAS:528:DC%2BD2MXhtlaltrzN (Pubitemid 41775908)
34. SV Rajkumar S Jacobus NS Callander, et al. 2010 Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 29 37 19853510 10.1016/S1470-2045(09)70284-0 1:CAS:528:DC%2BC3cXjslKrsg%3D%3D This pivotal study demonstrated inferior OS with high doses of dexamethasone combined with lenalidomide, despite better responses compared with weekly dexamethasone. These results changed practice, and high-dose dexamethasone is no longer used in this setting
35. JA Zonder J Crowley MA Hussein, et al. 2010 Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) Blood 116 5838 41 20876454 10.1182/blood-2010-08-303487 1:CAS:528:DC%2BC3MXktFyjtA%3D%3D
36. M Cavo G Perrone S Buttignol, et al. 2010 Bortezomib-thalidomide- dexamethasone compared with thalidomide-dexamethasone as induction and consolidation therapy before and after double autologous transplantation in newly diagnosed multiple myeloma: results from a randomized phase 3 study [abstract] ASH Annual Meeting Abstracts 116 42
37. PG Richardson E Weller S Lonial, et al. 2010 Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 116 679 86 20385792 10.1182/blood-2010-02-268862 1:CAS:528:DC%2BC3cXhtVCku7%2FE
38. P Kapoor S Kumar R Fonseca, et al. 2009 Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone Blood 114 518 21 19324902 10.1182/blood-2009-01- 202010 1:CAS:528:DC%2BD1MXpt1Wmsb4%3D
39. MQ Lacy MA Gertz A Dispenzieri, et al. 2007 Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma Mayo Clin Proc 82 1179 84 17908524 10.4065/82.10.1179 1:CAS:528:DC%2BD2sXhtF2hs7rK (Pubitemid 47502875)
40. JP Fermand P Ravaud S Chevret, et al. 1998 High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial Blood 92 3131 6 9787148 1:CAS:528:DyaK1cXntFCqsLs%3D (Pubitemid 28492319)
41. M Attal JL Harousseau T Facon, et al. 2003 Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2495 502 14695409 10.1056/NEJMoa032290 1:CAS:528:DC%2BD3sXhtVWit7vF (Pubitemid 38010075)
42. M Cavo P Tosi E Zamagni, et al. 2007 Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study J Clin Oncol 25 17 2434 41 17485707 10.1200/JCO.2006.10.2509 (Pubitemid 46999214)
43. P Sonneveld B van der Holt E Vellenga, et al. 2005 Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial [abstract] Blood (ASH Annual Meeting Abstracts) 106 2545
44. F Garban M Attal M Michallet, et al. 2006 Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Blood 107 3474 80 16397129 10.1182/blood-2005-09-3869 1:CAS:528:DC%2BD28Xkt1GitL4%3D
45. B Bruno M Rotta F Patriarca, et al. 2007 A comparison of allografting with autografting for newly diagnosed myeloma N Engl J Med 356 1110 20 17360989 10.1056/NEJMoa065464 1:CAS:528:DC%2BD2sXivVKit7Y%3D (Pubitemid 46425595)
46. A Krishnan MC Pasquini M Ewell, et al. 2010 Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by hla matched sibling non- myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial [abstract] ASH Annual Meeting Abstracts 116 41 This important phase 3 trial once again failed to show any benefit for allogeneic SCT in MM compared with tandem autologous SCT
47. M Attal JL Harousseau S Leyvraz, et al. 2006 Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood 108 3289 94 16873668 10.1182/blood-2006-05-022962 1:CAS:528:DC%2BD28Xht1ahs7fE
48. AK Stewart S Trudel NJ Bahlis, et al. 2010 A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): The NCIC CTG MY.10 Trial [abstract] ASH Annual Meeting Abstracts 116 39
49. M Attal VC Lauwers G Marit, et al. 2010 Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02 [abstract] ASH Annual Meeting Abstracts 116 310
50. PL McCarthy K Owzar KC Anderson, et al. 2010 Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract] ASH Annual Meeting Abstracts 116 37
51. GJ Morgan FE Davies WM Gregory, et al. 2010 First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial Lancet 376 1989 99 21131037 10.1016/S0140-6736(10)62051-X 1:CAS:528:DC%2BC3cXhsFCqsLnL This is the first randomized trial to show survival benefit with the use of bisphosphonates. In this trial, patients who did not have any lytic lesions at diagnosis also derived benefit in terms of reduction in skeletal events